Pratik Multani, M.D., is a distinguished medical professional who currently serves as the Chief Medical Officer at ORIC Pharmaceuticals Inc. Dr. Multani brings a wealth of experience to his role, with a career spanning over two decades in the biopharmaceutical industry. He earned his medical degree from the University of Pennsylvania School of Medicine and completed his residency in internal medicine at Stanford University Hospital. His expertise in oncology and hematology has been instrumental in guiding ORIC Pharmaceuticals' clinical development strategy. Prior to joining ORIC Pharmaceuticals, Dr. Multani held several key leadership positions at renowned organizations. He served as the Chief Medical Officer at both Trillium Therapeutics and Pharmacyclics, where he played a pivotal role in the development and approval of groundbreaking cancer therapies. At Pharmacyclics, he was instrumental in the successful development and launch of Imbruvica, a first-in-class Bruton's tyrosine kinase inhibitor that has transformed the treatment landscape for various B-cell malignancies. Dr. Multani's extensive experience in clinical development, regulatory affairs, and medical affairs has been crucial in advancing innovative therapies from early-stage research to market approval. As Chief Medical Officer at ORIC Pharmaceuticals, Dr. Multani is responsible for overseeing the company's clinical development programs and ensuring the successful execution of its pipeline. His leadership has been instrumental in advancing ORIC's mission to develop precision medicines for patients with genetically defined cancers. Dr. Multani's strategic vision and deep understanding of the oncology landscape have positioned ORIC Pharmaceuticals as a leader in the development of novel cancer therapies. His dedication to improving patient outcomes and his commitment to scientific excellence continue to drive the company's growth and success.